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Abstract
Cardiomyocyte cell death is a major contributing factor to various cardiovascular diseases and is therefore an important target for the design of
therapeutic strategies. More recently, stem cell therapies, such as transplantation of embryonic or induced pluripotent stem (iPS) cell-derived
cardiomyocytes, have emerged as a promising alternative therapeutic avenue to treating cardiovascular diseases. Nevertheless, survival of
these introduced cells is a serious issue that must be solved before clinical application. We and others have identified a small non-coding RNA,
microRNA-24 (miR-24), as a pro-survival molecule that inhibits the apoptosis of cardiomyocytes. However, these earlier studies delivered mim-
ics or inhibitors of miR-24 via viral transduction or chemical transfection, where the observed protective role of miR-24 in cardiomyocytes
might have partially resulted from its effect on non-cardiomyocyte cells. To elucidate the cardiomyocyte-specific effects of miR-24 when over-
expressed, we developed a genetic model by generating a transgenic mouse line, where miR-24 expression is driven by the cardiac-specific
Myh6 promoter. The Myh6-miR-24 transgenic mice did not exhibit apparent difference from their wild-type littermates under normal physiologi-
cal conditions. However, when the mice were subject to myocardial infarction (MI), the transgenic mice exhibited decreased cardiomyocyte
apoptosis, improved cardiac function and reduced scar size post-MI compared to their wild-type littermates. Interestingly, the protective effects
observed in our transgenic mice were smaller than those from earlier reported approaches as well as our parallelly performed non-genetic
approach, raising the possibility that non-genetic approaches of introducing miR-24 might have been mediated via other cell types than cardio-
myocytes, leading to a more dramatic phenotype. In conclusion, our study for the first time directly tests the cardiomyocyte-specific role of
miR-24 in the adult heart, and may provide insight to strategy design when considering miRNA-based therapies for cardiovascular diseases.
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Introduction
One of the immediate consequences of cardiac injury is cell death. In
a single event of myocardial infarction (MI), more than 25% of cardio-
myocytes can be wiped out [1]. The massive death of the contractile
muscle cells is followed by scar formation, dysfunction of the heart
and ultimately heart failure. Because the human heart has a limited
regenerative capacity, preventing the loss of existing cells and pro-
moting the generation of new cardiomyocytes are current approaches
being extensively studied.
Recent advances in direct cardiac reprogramming introduce a
new possibility of regenerating the heart by converting endogenous
cardiac fibroblasts (CFs) or other fibroblasts into cardiomyocyte-like
cells (mouse, [2–6]; human, [7–9]). The potential to utilize a large
pool of endogenous CFs to generate functional cardiomyocytes points
to a promising avenue to repairing the damaged myocardium in
human patients. However, the fact remains that most of the repro-
grammed CFs do not become fully matured, and that in vivo repro-
gramming has only worked thus far when the reprogramming factors
(such as Gata4, Mef2c and Tbx5 (GMT) in mice) are introduced at the
time of injury.
Another approach to regenerating the heart is to derive new car-
diomyocytes for transplantation. These cells are typically differenti-
ated from multipotent cardiovascular progenitor cells (CPCs) [10, 11]
or pluripotent stem cells, including both embryonic stem (ES) cells
[12–15] and induced pluripotent stem (iPS) cells [16, 17]. Although
efforts to make this a practical therapy are ongoing, the poor survival,
low maturational efficiency, limited cell–cell interaction and poor
functional integration of engrafted cells are major hurdles that remain
to be overcome [1].
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Alternatively, researchers are actively searching for factors that
regulate cardiomyocyte proliferation [18–20] and cell death [21–24]
to facilitate the regeneration of injured hearts. microRNAs (miRNAs)
are small non-coding RNAs that are typically 20-22 nucleotides in
length and play important roles in many biological processes [25–
27]. Because miRNAs’ short lengths facilitate easier and safer deliv-
ery, they are suitable candidates and/or targets for disease therapies.
However, the regulatory network of one microRNA can be rather com-
plicated, typically involving multiple targets by binding to their 30 UTR
regions via its ‘seed region’. A complete understanding of one micr-
oRNA’s functions under different contexts is, therefore, extremely
important for proper design of therapeutic strategies to avoid poten-
tial side effects.
The function of miR-24 in the heart is a good example of the
potential complexity of a single miRNA’s regulatory role. On the
one hand, miR-24 has been reported to be pro-survival. It has been
shown that miR-24 inhibits apoptosis in cardiomyocytes, and that
introduction of miR-24 into the heart significantly attenuates car-
diac dysfunction [24]. miR-24 was also found to promote CPC’s
functional engraftment in a study led by Hu et al., where miR-24
was used as part of an anti-apoptotic cocktail to promote the sur-
vival of stem cell-derived CPCs for transplantation into MI hearts
[28]. Additional pro-survival roles of miR-24 in cardiac fibrosis
were identified by Wang and colleagues, who found that overex-
pression of miR-24 in the MI heart by lentivirus-mediated transduc-
tion reduced fibrosis and improved heart function, confirming the
beneficial role of miR-24 when expressed under acute injury [29].
On the other hand, pro-apoptotic roles of miR-24 were also
reported. miR-24 was characterized as a pro-apoptotic microRNA
in endothelial cells in the heart, where injection of antagomir of
miR-24 that blocks its function prevented endothelial apoptosis,
enhanced vascularity and resulted in an improved heart function
after MI [30]. In a mouse hypertrophy model where the aorta was
constricted artificially, suppression of miR-24 protected the heart
from transitioning from compensated hypertrophy to decompensat-
ed hypertrophy through regulation of L-type Ca2+ channel-ryanodine
receptor signalling [31]. Therefore, the context-dependent function
of miR-24 in apoptosis is intriguing and worthy of further investi-
gation. Importantly, although significant advances have been made
in understanding the role of miR-24, there had been no simple
genetic model to precisely and directly test the cardiomyocyte-spe-
cific role of miR-24 in the heart.
In this article, we generated a cardiac-specific transgenic mouse
model of miR-24, in which we utilized the Myh6 promoter to drive the
expression of miR-24 in cardiomyocytes in the heart. We report here
that Myh6 promoter-driven miR-24 expression was sufficient to pro-
mote cardiomyocyte survival post-acute injuries. In addition, cardiac
overexpression of miR-24 resulted in scar size reduction and heart
function improvement. Furthermore, we investigated the molecular
pathway through which miR-24 functions and showed that miR-24
modulates intrinsic apoptosis in our transgenic model. Although a
milder effect was observed compared to the results from a non-
genetic approach [24], our findings support the anti-apoptotic role of
miR-24 in the heart, and suggest that additional effects may be medi-
ated through cell types other than cardiomyocytes.
Materials and methods
Mouse lines
To generate the Myh6-miR-24 mice, a cDNA construct containing a 400-
bp mouse genomic region encompassing the miR-24-2 locus was cloned
downstream of the mouse cardiac myosin heavy chain (aMHC/Myh6) pro-
moter. Primers used for cloning were: forward primer 50-CAC-
CATCTCCTCAGGCCGCTGCTG-30, reverse primer 50-CTATCTGCTTTG
GGGAACCACAG-30. Transgenic mice were produced by microinjection of
the Myh6-miR-24 construct into fertilized mouse embryos (C57BL/6
background). Three independent transgenic lines were established and
one line with a sixfold overexpression of miR-24 was extensively studied.
Transgenic mice were identified by PCR analysis of tail genomic DNA
using the forward primer 50-GCCCACACCAGAAATGACAGA-30 and the
reverse primer 50-CTATCTGCTTTGGGGAACCACAG-30. Functional studies,
gene expression and immunohistochemistry (IHC) were analysed in pairs
of Myh6-miR-24 (TG) and littermate non-transgenic (WT) male mice.
Immunohistochemistry
After perfusion fix with 4% paraformaldehyde (PFA, diluted from 20%
PFA stock, Electron Microscopy Sciences) in PBS, the heart was
removed and fixed by immersion in 4% PFA in PBS overnight at 4°C
and routinely processed and paraffin embedded. Sections (5 lm) were
stained with haematoxylin and eosin and analysed for regular morphol-
ogy. To measure the infarct size at 4 weeks after MI, left ventricles
(LVs) were cut from apex to base; sections from four equally distrib-
uted levels were AZAN- or Masson-Trichrome stained. Scar size was
calculated as the percentage of the LV circumference, or total scar area
divided by total LV area, and was summed from four transverse sec-
tions per heart. To quantify apoptotic cardiomyocytes, mouse hearts
were removed 24 hrs after coronary artery ligation and were fixed with
0.5% PFA in 5% sucrose and routinely frozen embedded in O.C.T and
processed for sectioning and staining with Caspase3 (rabbit, 1:200;
Sigma-Aldrich, St. Louis, MO, USA) or TUNEL and a-Actinin (mouse,
1:800; Sigma-Aldrich) as described [24]. TUNEL was performed with an
In Situ Cell Death Detection Kit, Fluorescein (Roche, Nutley, NJ, USA),
per the manufacturer’s protocol. DAPI was used for nuclear counter-
staining. Frozen heart sections were also stained with phospho-histone
H3 (rabbit, 1:100; Millipore-Upstate, Billerica, MA, USA), a-Actinin, and
DAPI to quantify proliferating cardiomyocytes; alternatively, sections
were stained with Wheat Germ Agglutinin (WGA; Alexa Fluor 488 Con-
jugate, Life Technology, Carlsbad, CA, USA, per the manufacturer’s pro-
tocols), a-Actinin, and DAPI to quantify cardiomyocyte size.
In vivo delivery of miR-24 mimic
With the chest open, oligos stabilized with 20-O-methyl modification
pre-treated with 20 ll of lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) were injected into the myocardium through an insulin syringe with
incorporated 29G needle (BD Biosciences, San Jose, CA, USA) into the
myocardium. One injection with a full dosage (40 ng of miR-24 mimic
or 40 ng of control mimic, ordered from Shanghai GenePharma Co.,
Shanghai, China) was employed along the boundary between the IZ and
BZ (based on the blanched infarct area) after coronary artery occlusion.
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After injection, the chest was closed with sutures and the mouse was
allowed to recover with mouse ventilator and heating pad.
Echocardiography
Echocardiography was performed with the Vevo 770 High-Resolution
Micro-Imaging System (VisualSonics, Toronto, ON, Canada) with a 15-
MHz linear array ultrasound transducer. The LV was assessed in both
parasternal long-axis and short-axis views at a frame rate of 120 Hz.
End-systole or end-diastole was defined as the phase in which the
smallest or largest area of LV, respectively, was obtained. Left ventricu-
lar end-systolic diameter (LVDS) and left ventricular end-diastolic diam-
eter (LVDD) were measured from the LV M-mode tracing with a sweep
speed of 50 mm/sec. at the papillary muscle level.
LAD ligation
All surgeries and subsequent analyses were performed in a blinded
fashion for genotype and intervention. Mice were anaesthetized with
2.4% isoflurane/97.6% oxygen and placed in a supine position on a
heating pad (37°C). Animals were intubated with a 19G stump needle
and ventilated with room air with a MiniVent Type 845 mouse ventilator
(Hugo Sachs Elektronik-Harvard Apparatus, March-Hugstetten, Germany;
stroke volume (SV) 250 ll, respiratory rate 120 breaths/min.). MI was
induced by permanent ligation of the left anterior descending artery
(LAD) with a 7-0 prolene suture as described [32]. Sham-operated
animals served as surgical controls and were subjected to the same
procedures as the experimental animals with the exception that the LAD
was not ligated. All surgical procedures were performed under aseptic
conditions. Four weeks or 24 hrs after occlusion, the heart was
removed for perfusion fix (4% PFA; paraffin sections for structural
analysis and IHC) or immersion fix (0.5% PFA in 5% sucrose; cryo sec-
tions for immunofluorescent staining); alternatively, the tissues within
the infarct zone (IZ), border zone (BZ) and non-ischaemic zone distal to
the infarct zone (DZ) were dissected for RNA or protein isolation.
Area at risk and infarct size
Twenty-four hours after coronary ligation, the mice were anaesthetized
and cannulated with tubing. A 2% Evans Blue solution (Sigma-Aldrich)
was perfused into the aorta, thus all myocardial tissue except the AAR
was stained blue. The LV was isolated and cut into four ~1 mm pieces
with first cut at the ligation level. LV slices were stained in 1.5% triphe-
nyltetrazolium chloride (TTC) for 30 min. at 37°C, and then fixed in 4%
PFA overnight at 4°C. The area of infarction was demarcated as a white
area, while viable myocardium was stained red. Photographs were taken
for both sides of each section. The AAR and the infarct area were deter-
mined via planimetry by using computer software ImagePro (Bio-Rad,
Hercules, CA, USA). Infarct size was calculated as the percentage of MI
compared with the AAR using a previously described methodology [33].
Real-time PCR
RNA was extracted using TRizol (Invitrogen). RT-PCR was performed with
the Superscript III first-strand synthesis system (Invitrogen). qPCR was
performed with the ABI 7900HT (TaqMan, Applied Biosystems, Carlsbad,
CA, USA), per the manufacturer’s protocols. Optimized primers from
Taqman Gene Expression Array were used. miRNA RT was conducted
using the Taqman MicroRNA Reverse Transcription Kit (Applied Biosys-
tems). miRNA real-time PCR (qRT-PCR) was performed per the manufac-
turer’s protocols by using primers from Taqman MicroRNA Assays
(Applied Biosystems). Expression levels were normalized to GAPDH
expression and miR-16 (microRNA qPCR) as previously reported [24].
Western blot
Western blots were performed as described [34]. Briefly, proteins were
separated by gel electrophoresis, transferred to the Hybond-P PVDF
membrane, blocked with 2% milk in PBST, incubated with primary and
HRP secondary antibodies, treated with luminol substrate and developed
on a film. Mouse monoclonal anti-caspase 8 (Sigma-Aldrich), mouse
monoclonal anti-caspase 9 (Sigma-Aldrich), rabbit anti-caspase 3
(Sigma-Aldrich), rat monoclonal anti-caspase 12 (Sigma-Aldrich) and
rabbit polyclonal antibody against Bim (amino acids 4–195 of BimEL
form) were all used at a 1:1000 dilution for Western blots.
Statistics
For echocardiography, TUNEL, Azan, Masson-Trichrome, Evans blue/
TTC staining quantification, statistical analysis was performed with
SPSS v.15. Comparisons between groups were made by one-way ANOVA
or Mann–Whitney U-test, as applicable. Sample numbers were indicated
in corresponding figures. For qPCR, we used biological triplicates and
technical triplicates; data were analysed by unpaired Student’s t-test.
Error bars indicate standard error of the mean (SEM). *P < 0.05,
**P < 0.01.
Results
Generation of Myh6-miR-24 transgenic mice
Previous studies revealed critical roles of miR-24 in promoting cell
survival, especially in murine cardiomyocytes, suggesting a potential
therapeutic application [24]. However, all of the in vivo studies so far
used non-genetic approaches, such as viruses and synthetic oligonu-
cleotides, to overexpress or inhibit miR-24. These approaches could
potentially affect other cell types including fibroblasts, endothelial
cells, circulating inflammatory cells and haematopoietic cells. To
investigate whether miR-24 exerts its effects primarily in the cardio-
myocytes to promote cell survival, we genetically targeted miR-24
under control of the cardiac-specific Myh6 promoter, which is pre-
dominantly activated after embryonic cardiac development [35].
Expression of mature miR-24 was quantified by qPCR, which revealed
that the transgenic mice had significantly higher levels of miR-24
expression than their control littermates (Fig. 1A). For detailed analy-
sis, we chose the line with a sixfold greater expression of miR-24, an
overexpression level not too high to overload the microRNA machin-
ery within the heart.
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Fig. 1Myh6-miR-24 transgenic mice exhibit elevated miR-24 expression, with no morphological or functional alteration under normal physiological
conditions. (A) Histogram showing miR-24 overexpression in three independent transgenic (tg) lines. Line #24 with sixfold overexpression was cho-
sen for extensive studies. n = 3 for each genotype. (B–E) Four-chamber and transverse sections with haematoxylin and eosin staining on control
and miR-24 hearts, both showing normal morphologies. (F and G) High magnification of sections from control (n = 5) and miR-24 tg (n = 6)
hearts, both showing normal cell morphology. (H) Table showing normal heart shape in both control (n = 16) and miR-24 tg (n = 16) mice. (I–J’)
Immunohistochemistry with WGA (green), a-Actinin (red) and DAPI counterstain (blue) on control and miR-24 tg heart sections. (K) Quantification
of cardiomyocyte width and length of control (n = 5) and miR-24 tg (n = 6) heart, showing no significant difference. (L–N) Histograms showing
normal cardiac function in both control (n = 16) and miR-24 tg (n = 16) mice. FS, fractional shortening; EF, ejection fraction; SV, stroke volume.
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miR-24 transgenic mice exhibited no significant
difference from their littermates under normal
physiological conditions
We first determined if a moderate overexpression of miR-24 in adult
cardiomyocytes could result in any morphological alteration in the
heart. Specifically, we examined the transgenic and wild-type control
hearts from mice ranging in age from 1 day to 10 weeks. Haematoxy-
lin and eosin staining on both 4-chamber view sections and trans-
verse sections revealed normal cardiac structures in the Myh6-miR-
24 transgenic mice compared to the littermate controls (Fig. 1B and
C). In addition, we quantified the length of LV anterior wall and LV
posterior wall to determine if overexpression of miR-24 in cardiomyo-
cytes could lead to wall thickening or thinning, and did not identify
such events (Fig. 1H, top).
When examined at high magnifications, cells within the hearts of
the transgenic mice exhibited normal morphologies (Fig. 1F and G).
To determine if there is difference in cardiomyocyte size and gross
sarcomere assembly, we co-stained heart sections with WGA, a-
Actinin and DAPI, and performed blinded quantification using stained
sections from four levels of LV. As shown in Figure 1I–K, no signifi-
cant difference was detected in cardiomyocyte size between trans-
genic and littermate control mice, neither was the gross sarcomere
assembly significantly different. These mice did not develop hyper-
trophy, hyperplasia, or heart failure when aged to 1–2 years (before
they died).
Next, we asked if expression of miR-24 in cardiomyocytes would
lead to any changes in heart function. We performed high-resolution
two-dimensional echocardiography on transgenic and control mice
when they were 1 and 2 months old (Fig. 1L–N). The fractional short-
ening (FS) of the ventricular chamber (FS) was not altered in trans-
genic mice compared to wild-type littermates (Fig. 1L); neither was
the fraction of blood ejected from the LV with each contraction (ejec-
tion fraction, EF) altered (Fig. 1M). Using an additional parameter to
assay the functional aspects of the heart, we determined the volume
of blood ejected with each heart beat (SV), and found no difference
between miR-24 transgenic mice and wild-type controls (Fig. 1N).
Furthermore, we measured the diameter of the left ventricle during
diastole (LVDD) and the diameter of the left ventricle during systole
(LVDS) on transgenic and control mice to further support our func-
tional measurements of EF, FS and SV. None of these parameters
showed significant difference between transgenic and wild-type mice
(Fig. 1H, bottom). These data indicate that cardiac miR-24 overex-
pression did not interfere with normal cardiac function and structure
under normal physiological conditions.
miR-24 promotes the survival of cardiomyocytes
cell autonomously upon injury
Our previous study using viral delivery of miR-24 mimics has shown
that miR-24 inhibits cardiomyocytes apoptosis both in vitro and
in vivo [24]. To follow-up, we wanted to determine if the anti-apoptotic
role of miR-24 is exerted directly on cardiomyocytes or through other
cell types. We combined Caspase 3 labelling with the cardiomyocyte
marker a-Actinin on infarcted mouse hearts from Myh6-miR-24 trans-
genic, wild-type littermate controls and mice treated with miR-24 mim-
ics (Fig. 2A–C’). The percentages of Caspase 3-positive (apoptotic)
cardiomyocytes in the IZ and BZ were lower in transgenic animals than
in control littermate mice, but with a milder effect compared to miR-24
mimics (Fig. 2D). This result was further confirmed by using another
apoptotic marker, TUNEL, in combination with a-Actinin (Fig. 2E–G’
and H). We detected no mitotic cardiomyocytes in either transgenic or
littermate control mice (data not shown). Compared to miR-24 expres-
sion using synthetic mimics, the anti-apoptotic effects were milder in
our transgenic mouse model (50–60% reduction versus 20–30%
reduction in % of apoptotic cardiomyocytes), suggesting that non-
autonomous function of miR-24 when delivered into other cells (e.g.
CFs) may help promote the survival of cardiomyocytes upon injury. In
fact, we have shown in the past that miR-24 is also expressed in CFs
but not in endothelial cells [24]. In situ hybridization using miR-24
LNA probe and qPCR further demonstrated that expression of miR-24
in myocardium was sharply reduced upon MI, but restored with miR-
24 mimic injection [24]. To further compare how our genetic model
differs from chemical delivery of miR-24 upon MI, we measured miR-
24 levels at injected area, border area and distant area in both Myh6-
miR-24 transgenic and miR-24 mimic-injected hearts (Fig. S1). In the
transgenic hearts, miR-24 had an even overexpression level, while in
mimic-injected hearts, miR-24 had a concentrated overexpression in
the injected area but an almost undetectable overexpression in the dis-
tant area (Fig. S1). miR-24 mimic injection resulted in a (locally)
higher overexpression compared to the transgenic model, which might
explain the stronger rescue in myocyte death. Nevertheless, our data
support the notion that miR-24 exerts at least part of its in vivo anti-
apoptotic function directly on cardiomyocytes.
Improved heart function in infarcted Myh6-
miR-24 transgenic mice
Myocardial infarction usually leads to functional decompensation
and heart failure after LV remodelling and cardiac fibrosis. We rea-
soned that if miR-24 prevents the cardiomyocytes from dying, its
overexpression in cardiomyocytes themselves would translate into
preservation of heart function. Therefore, we performed high-resolu-
tion two-dimensional echocardiography to compare the changes in
cardiac function after MI between transgenic and wild-type control
mice.
All mice showed initial reduction in LV function (FS and EF) after cor-
onary artery ligation, confirming successful induction of MI, while the
miR-24 transgenic mice showed alleviated reduction in all parameters
(Fig. 3A and B, Fig. S2A and B). Three days post-MI, miR-24 transgenic
mice showed a higher FS (15.10 + 0.54% versus 12.62 + 0.78%,
P < 0.05) and EF (32.76 + 1.68% versus 28.14 + 1.58%, P < 0.05)
compared to control littermates (Fig. 3C). Moreover, SV was significantly
higher in transgenic mice than controls (Fig. S2C). As an important con-
trol, we measured heart rate (HR) and found no difference between
transgenic and control mice (Fig. 3D), suggesting that the improvement
in heart function is because of better structure and contractility of the LV.
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To test if functional preservation persists over time, we performed
the same measurements at 4 weeks post-MI (Fig. 3A–C, Fig. S2A–
C). The absolute numbers of FS and EF remained statistically different
between transgenic and controls (Fig. 3C, Fig. S2A and B). Further-
more, the difference in SV became more significant between two
groups (Fig. S2C), suggesting that functional protection by overex-
pression of miR-24 in cardiomyocytes lasted for at least 4 weeks.
Although statistically significant, the increase in each function param-
eter was not as dramatic as from the previous study where miR-24
mimics were delivered virally (Fig. S3), suggesting additional benefi-
cial effects might be executed through other cell types than cardio-
myocytes.
Reduced scar size in infarcted Myh6-miR-24
transgenic mice
Cardiac fibrosis and scar formation are commonly resulted from ischae-
mia and shortage of oxygen in MI hearts. On the basis of the observation
that cardiomyocyte death was attenuated and cardiac function was
improved in Myh6-miR-24 transgenic mice, we tested if these would be
correlated with reduction in scar size. As an important control experi-
ment, we first determined if the inhibition of apoptosis by miR-24
expression in cardiomyocytes affected the degree of myocardial damage.
We performed Evans blue/TTC double staining to assess the area at risk
(AAR) and the infarct size of myocardium 24 hrs after coronary ligation.
Overexpression of miR-24 led to a decrease in infarct size but no change
in AAR (Fig. 4I), suggesting that miR-24 expression reduced cardiac
damage shortly after MI. Four weeks later, we examined the scar size by
performing AZAN staining on sections from multiple layers of LVs to
delineate both viable myocardium and scar area (Fig. 4A and B). After
blinded quantification on six sections from each of the four layers span-
ning LVs from seven control and eight transgenic mice, we found a
reduction in both scar area and circumference in transgenic mice com-
pared to controls (Fig. 4C and D). To further confirm our results, we per-
formed Masson-Trichrome staining, which is another commonly used
method for determining scar size in infarcted heart by differentially stain-
ing collagen (green), cytoplasm (pink), muscle fibres (red) and the nuclei
(black; Fig. 4E and F). Although we did not detect statistically significant







Fig. 2Myh6-miR-24 transgenic mice exhibit reduced cardiomyocyte apoptosis upon myocardial infarction. (A–C’) Immunocytochemistry with Cas-
pase 3 (red) and a-Actinin (green) labelling as well as DAPI counterstain (blue) on control (n = 9), miR-24 tg (n = 7) and miR-24 mimic-treated
(n = 5) hearts. (D) Quantification of apoptotic cardiomyocytes (Caspase 3- and a-Actinin-positive) in the infarct zone (IZ) and border zone (BZ), with
miR-24 tg and mimic-treated hearts showing reduced apoptosis. (E–H) Alternative staining and quantification of apoptotic cardiomyocytes (TUNEL-
and a-Actinin-positive) in IZ and BZ, with miR-24 tg and mimic-treated hearts showing reduced apoptosis. *P < 0.05. **P < 0.01.
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of collagen area as the readout (Fig. 4H), we found that the difference
became significant when using the area of collagen as the readout
(Fig. 4G). As the calculation of area is typically more reliable than the
calculation of circumference, potentially because of the irregular shape
of certain scars, we believe the Masson-Trichrome data support our
conclusion from AZAN staining. Meanwhile, it is important to notice
the attenuation of scar formation is moderate compared to other
published data where miR-24 was delivered non-genetically [24].
At the molecular level, miR-24 transgenic mice exhibited a
lower level of stress markers such as atrial natriuretic factor (ANF)
and brain natriuretic peptide (BNP), with partially restored levels of
dysregulated miRNAs. We performed qPCR to detecct the expres-
sion levels of ANF, BNP and several stress-responsive miRNAs
(miR-29, miR-195 and miR-208) in Myh6-miR-24 transgenic and
control hearts. Both ANF and BNP were up-regulated 24 hrs after
MI, while the up-regulation of ANF and BNP was attenuated in
miR-24 transgenic hearts (Fig. 4J), which is similar to miR-24
mimic-treated hearts [24] (Fig. S4). Similarly, miR-29, miR-195
and miR-208 were dramatically reduced upon MI, but were par-
tially restored by overexpression of miR-24 in cardiomyocytes
(Fig. 4K).
Taken all together, we provide evidence that miR-24 improves LV
function after MI by autonomous inhibition of cardiac cell death. How-
ever, the overall beneficial role of miR-24 in infarcted hearts is mild,
and in most cases expression of miR-24 solely in cardiomyocytes is
not able to revert the damaged myocardium close to normal.
miR-24 modulates intrinsic apoptosis by
suppressing Bim in a cell autonomous manner
We have previously demonstrated that miR-24 inhibits cardiomyo-
cytes apoptosis by targeting the pro-apoptotic Bcl2 family protein
Bim [24]. Therefore, we tested if miR-24 regulated the same apopto-
sis pathway in our transgenic model where miR-24 is intrinsically
overexpressed in cardiomyocytes. Proteins were extracted from the
infarct and BZs of infarcted transgenic and wild-type mouse hearts,
and then endogenous protein levels were analysed by Western blot.
Activated Caspase 3 was barely detectable in both uninjured trans-
genic and littermate controls (Fig. 5 left). However, after MI there
was a significant induction of Caspase 3 activity, which was less
prominent in miR-24 transgenic hearts (Fig. 5 right). Similarly, with-
out MI, no significant difference was observed for any caspase
between transgenic mice and littermate controls (Fig. 5 left). How-
ever, the increases in the expression levels of the ER-specific cas-
pase, Caspase 12 and the mitochondria-mediated apoptotic caspase,
Caspase 9, were significantly attenuated in infarcted mouse hearts
with miR-24 overexpression (Fig. 5 right). More importantly, the
increase in protein level of Bim after MI was reduced in these hearts
compared to controls (Fig. 5 right). Thus, we conclude that miR-24
inhibits Bim and regulates the intrinsic apoptosis in cardiomyocytes.
Discussion
It has been demonstrated that miR-24 plays a role in a variety of cell
types in the heart, including cardiomyocytes [24, 36], fibroblasts
[29], as well as endothelial cells [30]. This raises an interesting
question about which cell type(s) is(are) the primary target of miR-
24’s protective functions in the heart, particularly under acute injury.
Consistent with its expression in the adult cardiomyocyte, our study
using a cardiac-specific transgenic model demonstrates that miR-24
could directly promote cardiomyocytes survival cell autonomously.
We consistently observed that the mimic treatment has a stronger
effect compared to transgenic approach. Interestingly, we found that





Fig. 3Myh6-miR-24 transgenic mice exhi-
bit improved heart function upon myocar-
dial infarction. (A and B) Histograms
showing reduction in cardiac function in
control (n = 21) and miR-24 tg (n = 21)
hearts 3 days and 4 weeks after myocar-
dial infarction, with miR-24 tg hearts
showing alleviated reduction in cardiac
function. (C) Baseline and post-MI (3 days
and 4 weeks) measurements of FS and EF
in control (n = 21) and miR-24 tg
(n = 21) mice. miR-24 tg mice exhibit
better heart function compared to con-
trols. (D) Baseline and post-MI (3 days
and 4 weeks) measurements of heart rate
(HR) in control (n = 21) and miR-24 tg
(n = 21) mice, showing no significant dif-
ference between the two. *P < 0.05.
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overexpression is more consistent across areas in our genetic model.
It seems that such transgenic approach offers a cleaner and more
consistent way to promote the survival of CM upon injury albeit with
a milder effect. Delivery of miRNAs using synthetic mimics, however,
is more feasible for potential clinical application, while cautions have
to be exercised considering the possible side effects of drastic miR-
24 overexpression in the injection area. In addition, our data also sug-
gest that miR-24 could have a cell non-autonomous effect when
delivered into other cardiac cell types to promote the survival of the
cardiomyocytes upon injury. Therefore, it will be interesting to test
the pro-survival role of miR-24 in other cell types to device potential
microRNA-therapy in additional tissues or organs.
microRNAs, given their unique features, typically regulate multiple
targets in a very context-dependent manner. Like other microRNAs,
miR-24 regulates a wide range of biological processes, and could
exert seemingly opposite effects on different cell types. For example,
miR-24 promotes apoptosis in human umbilical vein endothelial cells
[30] and certain human cancer cell lines [37], while it inhibits apopto-
sis in other human cancer cell lines [38, 39], rodent cardiomyocytes
(mouse [24] and rat [40]), frog retinal cells [41] and mouse haemato-
poietic cells [42]. It is also interesting to note that miR-24 targets
different apoptotic pathway components when positively or negatively
regulating cell death. For example, pro-apoptotic genes such as FAF-1
[39], Caspase9 [24, 41], Bim [24] and Apaf-1 [41] were reported
to mediate miR-24’s anti-apoptotic function, while PAK4 and BAD
[30] were the targets that mediate miR-24’s pro-apoptotic role.
To elucidate miR-24’s regulatory roles, it is important to ascertain










Fig. 4Myh6-miR-24 transgenic mice exhibit reduced scar size, lowered stress marker expression and partial restoration of dysregulated miRNAs.
(A–D) Scar visualization by AZAN staining and scar size quantification on control (n = 7) and miR-24 tg (n = 8) hearts 4 weeks post-MI, with miR-
24 tg mice showing reduced scar size. LV, left ventricle. (E–H) Alternative scar size visualization and quantification by Masson-Trichrome staining.
Green = collagen; pink = cytoplasm; red = muscle fibres; black = nuclei. (I) Histogram showing size of area at risk (AAR) and size of infarct in con-
trol (n = 5) and miR-24 tg (n = 5) hearts 24 hrs after MI. miR-24 tg mice showed reduced infarct size. (J) Histograms showing relative expression
levels of stress markers atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP). miR-24 mice showed lowered levels of stress markers. IZ,
infarct zone; BZ, boarder zone. (K) Histograms showing relative expression levels of microRNAs miR-29a, miR-195 and miR-208. miR-24 mice
showed partial restoration of these miRNAs. *P < 0.05.
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Identification of the context-dependent downstream targets is also
necessary to fully understand miR-24’s cell type-specific roles. In
addition, characterization of co-regulators that restrict miR-24 to spe-
cific sets of targets in various tissues and cell types will undoubtedly
help define the regulatory network of miR-24.
Both overexpression and inhibition of miR-24 have been reported
to protect heart function upon injury [24, 29], [30, 31]. It is possible
that the contradictory results may be because of the different types of
viruses or synthetic oligos delivered into the hearts that may restrict
miR-24 expression primarily in one cell type than the other. The time
and location of delivery in the heart may also contribute to the
discrepancy. To determine the role of miR-24 in the heart more
precisely, we turned to genetic approach to specifically overexpress
miR-24 in the cardiomyocytes, and demonstrated that miR-24 could
directly prevent cardiomyocytes from undergoing apoptosis. It will be
interesting to determine if a similar or opposite effect can be observed
in endothelial specific miR-24 transgenics (e.g. Tie1-miR-24 or VE-
cadherin-miR-24) and/or fibroblast specific miR-24 transgenics (e.g.
Fsp1-miR-24 or Periostin-miR-24 or Tcf21-miR-24). In summary,
characterizing how miR-24 promotes cell survival in the heart is
a necessary next step for designing therapeutic strategies for
cardiovascular diseases.
It will also be interesting to consider the difference in the timing
of functional improvement between miR-24-mediated approach and
reprogramming factors-mediated approach. It is observed that little
or no improvement in cardiac function occurs until 8 weeks post-MI
when reprogramming approaches are used to regenerate the heart
[3], which is possibly attributable to the relatively long process of
conversion. However, the prevention of cell death in cardiomyocytes
resulted in a more immediate effect in functional improvement as
early as 3 days after injury [24]. This information is particularly help-
ful when considering the suitability of each approach for different
types of cardiac disease.
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Additional Supporting Information may be found in the online
version of this article:
Figure S1 Myh6-miR-24 transgenic mice exhibit a more uniform
miR-24 expression pattern compared to miR-24 mimic-treated mice.
Figure S2 Myh6-miR-24 transgenic mice exhibit heart function
impairment after MI, but show protection compared to control
littermates.
Figure S3 Myh6-miR-24 transgenic mice exhibit a milder pro-
tection effect compared to miR-24 mimic-treated mice after MI.
Figure S4 Gene expression of cardiac stress marker atrial natri-
uretic factor.
Fig. 5miR-24 regulates the intrinsic apoptosis pathways by suppressing
the pro-apoptotic protein Bim. Western blot shows little expression of
pro-apoptotic proteins Caspase 3, Caspase 12, Caspase 9 and Bim
under normal physiological conditions (no MI) and elevated expression
after myocardial infarction (MI). miR-24 mice showed reduced levels of
pro-apoptotic proteins after MI compared to controls.
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